Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075998 · ClinicalTrials.gov registry record · Phase 3
The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)
A Phase 3 study, sponsored by InterMune.
- Terminated
- Registry status
- Phase 3
- Development phase
- 826
- Enrollment target
NCT00075998: Clinical Trial Phase 3 study, sponsored by InterMune.
NCT00075998 is a Phase 3 study that was terminated before completion, run by InterMune. The registered enrollment target is 826 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00075998, a Phase 3 study, was terminated before completion, sponsored by InterMune.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 826 participants
- Enrollment target
Study Summary
* Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF * Enrollment: Approximately 800 patients will be enrolled from approximately 80 centers in North America and Europe * Randomization: 2:1 active-to-placebo ratio * Duration: at least 2 years active drug or placebo (rescue therapy will be permitted for patients who meet predefined criteria)
Interventions
- DRUG Interferon gamma-1b ("Actimmune")
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 826 participants |
| Start Date | 2003-12 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Why NCT00075998 stopped before completion
NCT00075998 is an interventional study that assigns participants to a tested intervention. The registered 826 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Interferon gamma-1b ("Actimmune") is the first listed.
NCT00075998 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00075998 about?
NCT00075998 is a clinical study titled "The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF)". * Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF * Enrollment: Approximately 800 patients will be enrolle...
What is the current status of trial NCT00075998?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 826 participants. The study started on 2003-12. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00075998?
The interventions under investigation include: Interferon gamma-1b ("Actimmune") (DRUG).
Who is sponsoring clinical trial NCT00075998?
This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00075998's enrollment target sits among peer trials
826 400th of 2000 higher than 1,601 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03547973 · 827 participants · Phase 2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- NCT05630482 · 825 participants · NA
Randomized Trial of Healthy Family Foundations
- NCT06097728 · 825 participants · Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- NCT07102641 · 825 participants · Phase 4
Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous Therapies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia